Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 4/20 | 0.68 |
| ▸ | CHRNA4 | P43681 | 5/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.46 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.44 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.44 |
| ▸ | ACACB | O00763 | 1/20 | 0.43 |
| ▸ | BPTF | Q12830 | 1/20 | 0.41 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.40 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.40 |
| ▸ | MGLL | Q99685 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL928388 | 0.89 | CHRNA7 (0.61) | CHRNA7CHRNA4CHRNB2HCRTR1HCRTR2 | |
| Trifluoroacetic Acid SCHEMBL22495370 | 0.83 | CHRNA7 (0.63) | CHRNA7CHRNA4CHRNB2BPTFCHRNB4 | |
| Trifluoroacetic Acid SCHEMBL30172159 | 0.83 | CHRNA7 (0.63) | CHRNA7CHRNA4CHRNB2BPTFCHRNB4 | |
| Trifluoroacetic Acid SCHEMBL1791576 | 0.81 | CHRNA7 (1.00) | CHRNA7CHRNA4CHRNB2CHRNB4CHRNA3 | |
| Trifluoroacetic Acid SCHEMBL25386682 | 0.80 | CHRNA7 (0.57) | CHRNA7CHRNA4CHRNB2 | |
| Trifluoroacetic Acid SCHEMBL928238 | 0.78 | CHRNA7 (0.57) | CHRNA7CHRNA4CHRNB2BPTFCHRNB4 | |
| Trifluoroacetic Acid SCHEMBL25386770 | 0.77 | CHRNA7 (0.52) | CHRNA7CHRNA4CHRNB2HCRTR1HCRTR2 | |
| Trifluoroacetic Acid SCHEMBL6330086 | 0.77 | CHRNA7 (0.56) | CHRNA7CHRNA4CHRNB2BPTFCHRNB4 | |
| Trifluoroacetic Acid SCHEMBL1792673 | 0.76 | CHRNB2 (0.67) | CHRNA7CHRNA4CHRNB2BPTF | |
| SCHEMBL1795279 | 0.76 | CHRNA7 (0.43) | CHRNA7CHRNA4CHRNB2ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2316836-A1 | Substituted diazabicycloalkane derivatives as ligands at alpha 7 nicotinic acetylcholine receptors | Abbott Laboratories (US) | 2011-05-04 | — | — | EP | disclosed |
| US-20050065178-A1 | Substituted diazabicycloakane derivatives | ABBOTT LABORATORIES | 2005-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065178-A1 | Substituted diazabicycloakane derivatives | CHRNA7, CHRNA1, CHRNA5 | CHRNA7 1/4885CHRNA4 9/4885CHRNB2 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.